^
    almost3years
    SENTI-101, a preparation of mesenchymal stromal cells engineered to express IL-12 and IL-21, induces localized and durable anti-tumor immunity in preclinical models of peritoneal solid tumors. (PubMed, Mol Cancer Ther)
    Consistent with this mechanism of action, co-administration of mSENTI-101 with checkpoint inhibitors leads to synergistic improvement in anti-tumor response. Collectively, these data warrant potential clinical development of SENTI-101 for patients with peritoneal carcinomatosis and high-grade ovarian cancer.
    Preclinical • Journal
    |
    IL21 (Interleukin 21)
    |
    SENTI-101
    almost4years
    [VIRTUAL] SENTI-101, a novel genetically modified allogeneic cell product expressing IL12 and IL21, elicits a tumor-localized, robust, and multimodal immune response in preclinical models of solid tumors (AACR-II 2020)
    In accordance with increased T-cell infiltration and activation in the TME, SENTI-101 showed a synergistic anti-tumor effect when combined with checkpoint inhibitor anti-PD1. Overall, our preclinical studies show that SENTI-101 modulates the tumor immune landscape via multiple complementary modes of action, resulting in long-term anti-tumor immunity. Furthermore, this work demonstrates the therapeutic potential of tumor-localized cell therapies armed with gene circuits expressing combinatorial immune effectors to trigger a multi-factorial anti-tumor response.
    PD(L)-1 Biomarker • IO biomarker
    |
    IFNG (Interferon, gamma) • CD38 (CD38 Molecule) • IL2RA (Interleukin 2 receptor, alpha) • CXCL9 (Chemokine (C-X-C motif) ligand 9) • GZMB (Granzyme B)
    |
    SENTI-101